Biotech Values

[jq1234]

I generally agree with your statement on "immunological adverse events".

As of CLDX's rindo, here is a retro analysis that could point to the effect of rindo on the expression of EGFRvIII at tumor recurrence. I find it very interesting:

http://jco.ascopubs.org/content/29/22/3105.2.full